Top

ESSA Pharma Inc.

TSXV Exchange | Aug 4, 2020, 10:30 AM EDT | Real-time price

EPI $ 9.30 RT
CHANGE
0.05 (0.5405%)
VOLUME
1,200
Day Low: 9.26
Day High: 9.30
Detailed Quote
Open: 9.27
High: 9.30
Beta: 1.6676
Shares Out.: 20,843,511
Total Shares (All Classes)2: 20,824,800
Prev. Close: 9.25
Low: 9.26
VWAP: 9.2917
Escrow Shares: 0
Market Cap (All Classes)2*: 193,670,640
Dividend: N/A
Div. Frequency: N/A
P/E Ratio: N/A
Listed Shares Out.1: 20,843,511
EPS: -1.38
Yield: N/A
Ex-Div Date: N/A
P/B Ratio: 3.131
Market Cap1: 193,844,652
Exchange: TSXV

(1) Number based only on listed classes of shares.

(2) Number sourced from third party data provider. For the most up to date information, please refer to the company's financial documents.

*Market Capitalization is based on Total Shares Outstanding for all share classes for the company. Convertible bonds and employee stock options that would otherwise be included in the Diluted Shares amount included in a company's filings/financials are not included.

Description

ESSA Pharma Inc is a pharmaceutical company. The company is in preclinical stage, focused on the development of small molecule drugs for the treatment of castration-resistant prostate cancer. The company is developing drugs which selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival. More

News Headlines for ESSA Pharma Inc.
Info TSX Venture

A comprehensive database of information on TSX Venture issuers

Show all links

Note: as part of an update to TMX Money, this link will be removed on June 30, 2020. Users wishing to access InfoTSXV can continue to do so directly

News Headlines for ESSA Pharma Inc.
Last 25 Trades
Copyright © QuoteMedia. Data delayed 15 minutes unless otherwise indicated. View delay times for all exchanges. Market Data powered by QuoteMedia, Fundamentals by Morningstar. See the QuoteMedia Terms of Use.